Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic neurostim

This article was originally published in The Gray Sheet

Executive Summary

Chronic pain neurostimulation implants RestoreAdvanced and PrimeAdvanced are launched in the U.S. Oct. 9. The devices add "advanced" features for improved ease of programming and automated customization of stimulation therapy to the firm's existing Restore rechargeable and RestorePrime nonrechargeable technology, Medtronic explains. The "sophisticated" programming "will greatly aid physicians in targeting each individual patient's specific stimulation area on the spinal cord that provides optimal pain relief ... referred to as the 'sweet spot,'" the firm claims...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024089

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel